Gene Expression Market Report 2026

The gene expression market size has grown rapidly in recent years. It will grow from $12.67 billion in 2025 to $14.16 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to growth in academic genomics research funding, increasing prevalence of chronic and genetic diseases, early adoption of microarray technologies, expansion of pharmaceutical R&D pipelines, rising use of PCR-based techniques.

The gene expression market size is expected to see rapid growth in the next few years. It will grow to $22.22 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to advancement in RNA sequencing technologies, increasing focus on precision medicine, growth in clinical diagnostics applications, integration of AI in gene expression data analysis, expanding biotechnology industry investments. Major trends in the forecast period include expansion of single-cell gene expression analysis, increasing use of spatial transcriptomics, growing demand for high-throughput PCR platforms, rising adoption of multi-omics integration, standardization of gene expression workflows.

The increasing prevalence of chronic diseases is expected to drive the growth of the gene expression market in the coming years. Chronic diseases are long-term medical conditions that persist for extended periods, typically three months or more. Gene expression analysis is employed in chronic diseases to uncover the molecular mechanisms underlying these conditions, identify potential biomarkers, and develop targeted therapies. For example, in June 2024, the National Health Service, a UK-based government agency, reported that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023 - a rise of 18% from 3,065,825 cases in 2022. Therefore, the growing prevalence of chronic diseases is expected to fuel the expansion of the gene expression market.

Leading companies in the gene expression market are focusing on developing innovative products, such as gene detection assays, to gain a competitive edge and boost revenue. A gene detection assay is a technique used to identify and quantify specific genetic molecules, providing insights into the activity and abundance of particular genes. For example, in January 2023, Bio-Techne Corporation, a U.S.-based biotech company specializing in research instruments, expanded its Advanced Cell Diagnostics (ACD)-branded RNAscope in situ hybridization (ISH) portfolio by launching the RNAscope Plus smRNA-RNA detection assay. This assay enables the simultaneous fluorescent detection of a small regulatory RNA along with three target RNAs or RNA biomarkers within a single tissue section, offering single-cell and subcellular resolution. Designed for large-scale studies, the assay is compatible with the Leica Bond Rx platform and is also available as a manual assay for convenient use. These therapeutic nucleic acids can modulate the expression and function of specific target genes, supporting the development of personalized treatments for inherited or acquired diseases that are resistant to conventional therapies.

In January 2023, Qiagen NV, a Germany-based molecular testing solutions company, acquired Verogen for an undisclosed sum. Through this acquisition, Qiagen obtained full access to Verogen’s GEDmatch database and GEDmatch PRO portal, along with exclusive distribution rights for a version of the MiSeq sequencer specifically designed for forensic applications. Verogen is a U.S.-based company specializing in DNA-based biometric human identification products.

Major companies operating in the gene expression market are Thermo Fisher Scientific Inc., Qiagen NV, Illumina Inc., Bio-Rad Laboratories Inc., Agilent Technologies Inc., PerkinElmer Inc., GE Healthcare, F Hoffmann-La Roche Ltd, Oxford Gene Technology IP Limited, Promega Corporation, OriGene Technologies Inc., Luminex Corporation, Takara Bio Inc., Danaher Corporation, ELITechGroup, Biocartis Group NV, Integragen SA, Oxford Nanopore Technologies Limited, Phalanx Biotech Group, Roche Holding AG, Sengenics Corporation Pte Ltd., GenXPro GmbH, Twist Bioscience Corporation, Zymo Research Corporation, Abcam plc., Bio-Techne Corporation.

North America was the largest region in the gene expression market in 2025. Asia-Pacific is expected to be the fastest-growing region in the gene expression market in the forecast period. The regions covered in the gene expression market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene expression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the gene expression market by increasing costs of imported kits, reagents, DNA chips, and laboratory instruments used across research and diagnostic workflows. These cost pressures have impacted drug discovery, clinical diagnostics, and biotechnology applications, with Asia-Pacific and Europe being most affected due to their reliance on cross-border supply chains. Tariffs have also delayed procurement cycles for high-end PCR systems and microarrays. However, they have encouraged regional manufacturing, local sourcing of consumables, and investments in domestic reagent production, supporting long-term supply chain resilience.

The gene expression market research report is one of a series of new reports that provides gene expression market statistics, including gene expression industry global market size, regional shares, competitors with a gene expression market share, detailed gene expression market segments, market trends and opportunities, and any further data you may need to thrive in the gene expression industry. This gene expression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene expression is the process by which the information encoded in a gene is used to produce a functional product, such as a protein. Proteins assembled through gene expression play a key role in determining cellular functions.

The main products in the gene expression market include kits and reagents, DNA chips or microarrays, and others. Kits and reagents are testing tools used to detect specific substances in the field or laboratory. Key processes include sample collection, purification, cDNA synthesis and conversion, PCR analysis, and data analysis and interpretation. Techniques used encompass RNA expression, promoter analysis, protein expression, and post-translational modification analysis. These products and techniques are applied across areas such as drug discovery and development, clinical diagnostics, biotechnology, microbiology, and more.

The gene expression market includes revenues earned by entities by providing services such as transcription, mRNA processing, non-coding RNA maturation, RNA export, translation, folding, translocation, and protein transport. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.